Bruker (NASDAQ:BRKR) Issues FY 2026 Earnings Guidance

Bruker (NASDAQ:BRKR) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 2.100-2.150 for the period, compared to the consensus estimate of 2.130. The company issued revenue guidance of $3.6 billion-$3.6 billion, compared to the consensus revenue estimate of $3.5 billion.

Wall Street Analyst Weigh In

A number of analysts have recently commented on BRKR shares. Wells Fargo & Company increased their target price on shares of Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. The Goldman Sachs Group started coverage on Bruker in a report on Tuesday, December 9th. They issued a “sell” rating and a $40.00 price objective for the company. UBS Group upped their target price on Bruker from $40.00 to $43.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. TD Cowen reissued a “hold” rating on shares of Bruker in a research report on Wednesday, January 7th. Finally, Zacks Research upgraded Bruker from a “strong sell” rating to a “hold” rating in a research note on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $52.08.

Bruker Stock Performance

Shares of Bruker stock opened at $37.51 on Friday. The company has a 50 day moving average of $47.15 and a 200-day moving average of $40.55. The company has a current ratio of 1.85, a quick ratio of 0.91 and a debt-to-equity ratio of 0.81. Bruker has a 1-year low of $28.53 and a 1-year high of $56.22. The company has a market cap of $5.70 billion, a PE ratio of -234.44, a price-to-earnings-growth ratio of 5.58 and a beta of 1.19.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). The firm had revenue of $977.20 million during the quarter, compared to the consensus estimate of $964.61 million. Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The firm’s revenue was down .2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.76 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, equities research analysts forecast that Bruker will post 2.69 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Mark Munch sold 7,000 shares of Bruker stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $55.00, for a total value of $385,000.00. Following the completion of the transaction, the vice president directly owned 128,443 shares of the company’s stock, valued at approximately $7,064,365. This trade represents a 5.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 27.30% of the stock is owned by company insiders.

Bruker News Summary

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Revenue beat and full press release — Q4 revenue came in above Street expectations and the company released its full Q4 & FY2025 report (includes results and guidance). Read More.
• Positive Sentiment: FY2026 top-line guidance raised — Bruker issued revenue guidance around $3.6B (above consensus ~$3.5B) and EPS guidance of $2.10–$2.15, roughly in line with consensus, signaling expected sales strength for the year. Read More.
• Neutral Sentiment: Business development: partnership in India — Bruker Spatial Biology announced a collaboration with Premas Life Sciences to expand tissue-research capabilities in India; positive for longer-term addressable market but limited near-term financial impact. Read More.
• Neutral Sentiment: Conference materials available — The company posted its press release, slide deck and conference call recording/slides for investors to review management commentary and detail behind guidance. Read More.
• Neutral Sentiment: Short-interest data appears unreliable — Multiple short-interest entries show “0 shares” / NaN changes (data glitch); not actionable until clean data is available.
• Negative Sentiment: EPS miss and margin pressure — Q4 EPS of $0.59 missed the consensus ~$0.65 and fell from $0.76 a year ago; Bruker reported a slight negative net margin, raising near-term earnings concern despite revenue strength. Read More.
• Negative Sentiment: Revenue flat to slightly down y/y — Revenue was essentially flat (down ~0.2% y/y), which with the EPS miss highlights margin/composition issues (pricing, mix or costs) that investors will monitor closely. Read More.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Los Angeles Capital Management LLC bought a new stake in Bruker during the fourth quarter worth $26,000. Parallel Advisors LLC boosted its holdings in Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after acquiring an additional 479 shares during the last quarter. Allworth Financial LP grew its stake in shares of Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares in the last quarter. EverSource Wealth Advisors LLC grew its stake in shares of Bruker by 51.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock worth $114,000 after acquiring an additional 942 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Bruker by 56.0% in the second quarter. Tower Research Capital LLC TRC now owns 4,172 shares of the medical research company’s stock valued at $172,000 after purchasing an additional 1,497 shares during the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.